Gossamer Bio, Inc.
GOSS
$1.13
-$0.125-10.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 114.70M | 105.32M | 95.84M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.70M | 105.32M | 95.84M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 114.70M | 105.32M | 95.84M | -- | -- |
| SG&A Expenses | 36.13M | 35.80M | 36.58M | 37.89M | 38.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.62M | 168.14M | 165.23M | 167.76M | 173.73M |
| Operating Income | -59.92M | -62.82M | -69.39M | -167.76M | -173.73M |
| Income Before Tax | -55.64M | -68.34M | -76.42M | -172.58M | -179.82M |
| Income Tax Expenses | 893.00K | 3.30M | 4.44M | -- | -- |
| Earnings from Continuing Operations | -56.53 | -71.65 | -80.85 | -172.58 | -179.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.53M | -71.65M | -80.85M | -172.58M | -179.82M |
| EBIT | -59.92M | -62.82M | -69.39M | -167.76M | -173.73M |
| EBITDA | -59.09M | -61.80M | -68.20M | -166.36M | -172.12M |
| EPS Basic | -0.40 | -0.32 | -0.39 | -1.05 | -1.38 |
| Normalized Basic EPS | -0.33 | -0.20 | -0.24 | -0.66 | -0.87 |
| EPS Diluted | -0.40 | -0.32 | -0.39 | -1.06 | -1.39 |
| Normalized Diluted EPS | -0.34 | -0.20 | -0.25 | -0.66 | -0.87 |
| Average Basic Shares Outstanding | 904.91M | 903.71M | 870.25M | 739.47M | 608.61M |
| Average Diluted Shares Outstanding | 917.23M | 916.03M | 882.57M | 739.47M | 608.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |